Press Releases

Date	Title
7/30/12	Sarepta Therapeutics to Present Company Overview at the Wedbush PacGrow Life Sciences Management Access Conference
7/27/12	Sarepta Therapeutics Regains NASDAQ Compliance
7/24/12	Sarepta Therapeutics Announces Significant Clinical Benefit With Eteplirsen After 36 Weeks in Phase IIb Study for the Treatment of Duchenne Muscular Dystrophy
7/23/12	Sarepta Announces Conference Call and Webcast on Tuesday, July 24, 2012, to Discuss 36-Week 6-Minute Walk Test Results From the Phase IIb DMD Study
7/19/12	Sarepta's Marburg Virus Drug Shows Survival in Primates Despite Delayed Treatment
7/12/12	AVI BioPharma Announces Corporate Name Change to Sarepta Therapeutics and Stock Ticker Symbol Change to "SRPT" Effective Today
7/6/12	AVI BioPharma to Present Company Overview at the Seventh Annual JMP Securities Healthcare Conference
6/1/12	AVI BioPharma Receives NASDAQ Notice of Minimum Bid Price Non-Compliance
5/10/12	AVI BioPharma Announces First Quarter 2012 Financial Results and Recent Corporate Developments
5/3/12	AVI BioPharma Announces First Quarter 2012 Financial Results and Corporate Update Conference Call

IR Menu